The goal of our study was therefore to sequence the VHL tumor suppressor gene in 360 ccRCC patients and characterize missense mutations by focusing on preferentially affected sites in the gene and their potential consequences on pVHL function and its binding partners. The gene discussed is VHL; the disease is nonpapillary renal cell carcinoma.